Literature DB >> 20456287

Behavioral evidence for the significance of serotoninergic (5-HT) receptors in cocaine addiction.

Małgorzata Filip1, Natalia Alenina, Michael Bader, Edmund Przegaliński.   

Abstract

Cocaine addiction has somatic, psychological, psychiatric, socio-economic and legal implications in the developed world. Presently, there is no medication approved for the treatment of cocaine addiction. In recent years, data from the literature (pre-clinical studies and clinical trials) have provided several lines of evidence that serotonin (5-HT) and 5-HT receptors play a modulatory role in the mechanisms of action of cocaine. Here we review the contribution of 5-HT receptor subtypes to cocaine sensitization, discrimination, conditioned place preference, self-administration, reinstatement of seeking behavior and withdrawal symptoms in laboratory animals. Additionally, the consequences of chronic cocaine exposure on particular 5-HT receptor-assigned functions in pre-clinical studies are presented.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20456287     DOI: 10.1111/j.1369-1600.2010.00214.x

Source DB:  PubMed          Journal:  Addict Biol        ISSN: 1355-6215            Impact factor:   4.280


  29 in total

Review 1.  Pharmacotherapeutics directed at deficiencies associated with cocaine dependence: focus on dopamine, norepinephrine and glutamate.

Authors:  Colin N Haile; James J Mahoney; Thomas F Newton; Richard De La Garza
Journal:  Pharmacol Ther       Date:  2012-01-31       Impact factor: 12.310

Review 2.  l-tetrahydropalamatine: a potential new medication for the treatment of cocaine addiction.

Authors:  Jia Bei Wang; John R Mantsch
Journal:  Future Med Chem       Date:  2012-02       Impact factor: 3.808

3.  Memory re-consolidation and drug conditioning: an apomorphine conditioned locomotor stimulant response can be enhanced or reversed by a single high versus low apomorphine post-trial treatment.

Authors:  Marinete Pinheiro Carrera; Robert J Carey; Flávia Regina Cruz Dias; Liana Wermelinger de Mattos
Journal:  Psychopharmacology (Berl)       Date:  2011-09-16       Impact factor: 4.530

4.  Sertraline delays relapse in recently abstinent cocaine-dependent patients with depressive symptoms.

Authors:  Alison Oliveto; James Poling; Michael J Mancino; D Keith Williams; Jeff Thostenson; Rhonda Pruzinsky; Kishorchandra Gonsai; Mehmet Sofuoglu; Gerardo Gonzalez; Shanti Tripathi; Thomas R Kosten
Journal:  Addiction       Date:  2011-10-10       Impact factor: 6.526

5.  Aripiprazole effects on self-administration and pharmacodynamics of intravenous cocaine and cigarette smoking in humans.

Authors:  Michelle R Lofwall; Paul A Nuzzo; Charles Campbell; Sharon L Walsh
Journal:  Exp Clin Psychopharmacol       Date:  2014-01-27       Impact factor: 3.157

Review 6.  Advancing addiction treatment: what can we learn from animal studies?

Authors:  Peter H Wu; Kalynn M Schulz
Journal:  ILAR J       Date:  2012

7.  Temporal pattern of cocaine intake determines tolerance vs sensitization of cocaine effects at the dopamine transporter.

Authors:  Erin S Calipari; Mark J Ferris; Benjamin A Zimmer; David C S Roberts; Sara R Jones
Journal:  Neuropsychopharmacology       Date:  2013-05-30       Impact factor: 7.853

8.  Cocaine sensitization increases I h current channel subunit 2 (HCN₂) protein expression in structures of the mesocorticolimbic system.

Authors:  Bermary Santos-Vera; Rafael Vázquez-Torres; Hermes G García Marrero; Juan M Ramos Acevedo; Francisco Arencibia-Albite; María E Vélez-Hernández; Jorge D Miranda; Carlos A Jiménez-Rivera
Journal:  J Mol Neurosci       Date:  2012-12-01       Impact factor: 3.444

9.  Efficacy of buspirone for attenuating cocaine and methamphetamine reinstatement in rats.

Authors:  Keith L Shelton; Elizabeth S Hendrick; Patrick M Beardsley
Journal:  Drug Alcohol Depend       Date:  2013-01-29       Impact factor: 4.492

10.  Risk neurogenes for long-term spaceflight: dopamine and serotonin brain system.

Authors:  N K Popova; A V Kulikov; E M Kondaurova; A S Tsybko; E A Kulikova; I B Krasnov; B S Shenkman; E Yu Bazhenova; N A Sinyakova; V S Naumenko
Journal:  Mol Neurobiol       Date:  2014-08-02       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.